Firstly, the landmark KEYNOTE-024 phase III study conducted by Reck and colleagues reported the superiority of the PD-1 inhibitor pembrolizumab over standard chemotherapy for NSCLC patients with PD-L1 Tumor Proportion Score (TPS) ≥ 50% [5]. Here, CD274 is linked to non-small cell lung carcinoma.